Jamaica faces the imminent collapse of its legal cannabis industry due to systemic governance failures and lack of political commitment, according to Dr. Henry Lowe, a foundational figure in medical cannabis research. The renowned scientist, who co-developed one of the world’s first cannabis-derived glaucoma treatments, asserts that institutional timidity and regulatory confusion have squandered the nation’s pioneering advantage.
Dr. Lowe’s critique highlights how Jamaica’s early breakthrough in cannabis medicine—including the revolutionary glaucoma eye drops he developed with colleagues—failed to translate into commercial leadership. While global markets expanded, foreign entities capitalized on Jamaican research and genetic resources without adequate local benefit. “What was developed here was commercialized elsewhere,” Lowe noted, emphasizing that decisive action could have prevented this intellectual drainage.
The researcher sharply distinguishes between medical and recreational use, advocating for regulated medical applications while expressing concern about uncontrolled consumption. “Cannabis is a drug requiring proper dosage and purpose,” he stressed, underscoring the necessity of medical frameworks for safety and efficacy.
Lowe attributes the industry’s underperformance to successive administrations from both major political parties (PNP and JLP) that offered rhetorical support but failed to implement effective policies. He particularly criticized the Cannabis Licensing Authority’s conflicting dual role as both regulator and promoter, arguing that this fundamental design flaw inhibits progress. Additional coordination gaps between the Ministry of Health and other agencies have further stalled development.
Unless immediate corrective measures are implemented, Lowe warns of total industry collapse. “I only see the negative aspects highlighted in media,” he observed, noting that without urgent structural reforms, Jamaica’s medical cannabis sector faces irreversible decline.